Japan stands firm over pricing system despite US pressure
This article was originally published in Clinica
Efforts by industry in the US over the past few years to push Japan into improving its by-function pricing system for medical devices have made little impact. This comes as a great disappointment to US industry, which has repeatedly called for Japan to expand the system's functional categories to allow the recognition of new technology in medical devices - in particular pacemakers, PTCA catheters and orthopaedic implants (see Clinica No 881, p 7).
You may also be interested in...
Issues over supply and the use of a skinny label have the potential to take a toll on the market for the fish oil drug icosapent ethyl, one analyst has claimed in the wake of Hikma’s recent generic launch.
The German Bundestag has adopted the Unified Patent Court’s draft ratification bill with the necessary qualified majority.
UK-based charity International Health Partners has launched a fresh appeal to double the value funds being raised to send essential medicines to expectant mothers and children at risk of death in areas of extreme deprivation.